With nothing to soften the blow when commodity prices fall, their revenues and earnings will take a hit. And investors won't ...
That question was on the minds of millions of investors on Thursday, as the Nasdaq Composite ( ^IXIC -5.52%) had one of its ...
Another growth driver will be AI coding, thanks to SpaceX's recent acquisition of Cursor. Cursor is essentially a workflow ...
Palantir stock is selling off despite another round of strong quarterly results. Where does the stock go from here?
Management's 2027 portfolio plan is still unproven, and the question is whether pricing discipline can lift a 46.8% gross ...
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years
Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company’s diversification efforts are slowly ...
When the stock market is volatile, some caution in investing might be warranted. The market is led by a handful of AI stocks ...
Management is betting on pricing changes and buyer behavior over near-term customer counts, a trade-off that likely defines ...
Its share buyback plan rests on cash from refranchising clubs, a tension the 8% revenue outlook alone does not resolve.
Fast lifecycle approvals, such as Simparica Duo, are how Zoetis plans to extend its core franchises beyond today's pressured ...
Supply chain moves taken last year, like buying memory chips early, are what protect fourth-quarter deliveries for ...
The world's most valuable company has seen its stock price plummet about 15% since Oct. 6, down to $203 per share as of Nov.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results